Harvard Management Company’s Fulcrum Therapeutics FULC Stock Holding History

Harvard Management Company’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-341,972	Closed	-$1.13M	–	24
2023 Q2	$1.13M	Sell	341,972 -68,742	-17%	-$202K	0.11%	25
2023 Q1	$1.17M	Hold	410,714	–	–	0.12%	40
2022 Q4	$2.99M	Hold	410,714	–	–	0.37%	29
2022 Q3	$3.32M	Hold	410,714	–	–	0.41%	27
2022 Q2	$2.01M	Hold	410,714	–	–	0.23%	34
2022 Q1	$9.71M	Hold	410,714	–	–	0.98%	13
2021 Q4	$7.27M	Hold	410,714	–	–	0.68%	32
2021 Q3	$11.6M	Hold	410,714	–	–	0.68%	21
2021 Q2	$4.3M	Hold	410,714	–	–	0.25%	27
2021 Q1	$4.84M	Hold	410,714	–	–	0.27%	29
2020 Q4	$4.81M	Hold	410,714	–	–	0.26%	20
2020 Q3	$3.26M	Hold	410,714	–	–	0.18%	21
2020 Q2	$7.51M	Hold	410,714	–	–	0.64%	14
2020 Q1	$4.9M	Hold	410,714	–	–	0.77%	12
2019 Q4	$6.83M	Hold	410,714	–	–	0.72%	12
2019 Q3	$2.73M	Buy	+410,714	New	+$4.54M	0.25%	15

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Harvard Management Company's FULC Position: Q3 2023 in Review

Harvard Management Company sold out of Fulcrum Therapeutics (FULC) in Q3 2023, closing a stake of 341,972 shares — an estimated $1.13M sold.

Harvard Management Company first reported a position in FULC in Q3 2019 and held it in 16 quarters. The position peaked at $11.6M in Q3 2021. 81 funds tracked by Wall St. Rank hold FULC as of Q3 2023.

Harvard Management Company reported no remaining Fulcrum Therapeutics position as of Q3 2023 after selling out during the quarter.
Harvard Management Company sold 341,972 Fulcrum Therapeutics shares in Q3 2023, an estimated $1.13M.
Harvard Management Company first reported a position in Fulcrum Therapeutics in Q3 2019 and held it in 16 quarters.
Harvard Management Company's Fulcrum Therapeutics position peaked at $11.6M in Q3 2021.
81 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2023.

Based on Harvard Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.